| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374677 | Bioorganic & Medicinal Chemistry Letters | 2010 | 7 Pages |
Abstract
A series of (3R,4R)-pyrrolidine-3,4-dicarboxylic acid amides was investigated with respect to their factor Xa inhibitory activity, selectivity, pharmacokinetic properties, and ex vivo antithrombotic activity. The clinical candidate from this series, R1663, exhibits excellent selectivity against a panel of serine proteases and good pharmacokinetic properties in rats and monkeys. A Phase I clinical study with R1663 has been finalized.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
![Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} as a clinical candidate](/preview/png/1374677.png "First Page Preview: Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} as a clinical candidate")
Authors
Lilli Anselm, David W. Banner, Jörg Benz, Katrin Groebke Zbinden, Jacques Himber, Hans Hilpert, Walter Huber, Bernd Kuhn, Jean-Luc Mary, Michael B. Otteneder, Narendra Panday, Fabienne Ricklin, Martin Stahl, Stefan Thomi, Wolfgang Haap,